Reversion of the Inflammatory Markers in Patients With Chronic Limb-Threatening Ischemia

Overview

Journal J Am Heart Assoc

Specialty Cardiology & Vascular Diseases

Date 2024 Apr 12

PMID 38606780

Authors

Joana Ferreira

Susana Roque

Alexandre Lima Carneiro

Adhemar Longatto-Filho

Isabel Vila Nurse

Cristina Cunha

Cristina Silva

Amilcar Mesquita

Jorge Cotter

Margarida Correia-Neves

Armando Mansilha

Pedro Guimaraes Cunha

Affiliations

Soon will be listed here.

Abstract

Background: Peripheral artery disease is characterized by an intense inflammatory process that can be associated with a higher mortality rate, particularly in chronic limb-threatening ischemia (CLTI). This study aims to compare the evolution of inflammatory markers between patients with claudication with those with CLTI at 3, 6, and 12 months.

Methods And Results: An observational, single-center, and prospective study was conducted. A total of 119 patients with peripheral artery disease (65 with claudication and 54 with CLTI) were observed and inflammatory markers collected at admission and 3, 6, and 12 months. At admission, patients with CLTI, when compared with patients with claudication, had significantly higher serum levels of C-reactive protein and fibrinogen (positive acute-phase proteins) and lower serum level of albumin, total cholesterol, and high-density lipoprotein (negative acute-phase proteins): C-reactive protein (g/dL), 2.90 (25th-75th percentile, 2.90-4.90) versus 6.80 (25th-75th percentile, 2.90-53.26) (=0.000); fibrinogen (mg/dL), 293.00 (25th-75th percentile, 269.25-349.00) versus 415.50 (25th-75th percentile, 312.00-615.75) (=0.000); total cholesterol (mg/dL), 161.79±95% [152.74-170.85] versus 146.42%±95% [135.30-157.53] (=0.034); high-density lipoprotein (mg/dL), 50.00 (25th-75th percentile, 41.00-60.00) versus 37.00 (25th-75th percentile, 30.00-45.50) (=0.000); albumin (g/dL): 4.00 (25th-75th percentile, 3.70-4.20) versus 3.60 (25th-75th percentile, 3.10-4.00) (=0.003). The association between CLTI and total cholesterol was lost after adjusting for confounders. Three months after the resolution of the CLTI, there was an increase in the levels of negative acute-phase proteins and a decrease in positive acute-phase proteins. These inflammatory proteins did not register an evolution in patients with claudication. The differences in the inflammatory proteins between groups disappeared at 6 months.

Conclusions: CLTI has an inflammatory environment that can be partially reverted after resolution of the ischemic process, emphasizing the importance of timely intervention.

Citing Articles

Berbamine Promotes the Repair of Lower Limb Muscle Damage in Chronic Limb-Threatening Ischemia by Inhibiting Local Inflammation and NF-κB Nuclear Translocation.

Zheng L, Zhao B, Zhang Z, Liu Y, Zhang Y, Cai J Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770425 PMC: 11679954. DOI: 10.3390/ph17121583.

Association of the Naples Prognostic Score with Long-Term Adverse Events in Chronic Limb-Threatening Ischemia After Below-the-Knee Endovascular Revascularization.

Dervis E, Hakgor A, Goksu M, Yakut I, Konte H, Panc C Diagnostics (Basel). 2024; 14(23).

PMID: 39682536 PMC: 11639753. DOI: 10.3390/diagnostics14232627.

References

Cauley J, Kassem A, Lane N, Thorson S . Prevalent peripheral arterial disease and inflammatory burden. BMC Geriatr. 2016; 16(1):213. PMC: 5148838. DOI: 10.1186/s12877-016-0389-9. View

Rudofsky G, Strubel G, Michler E, Kuegler C, Biro F . Influence of fibrinogen and hematocrit on the early outcome of angioplasty in patients with PAOD. J Endovasc Ther. 2004; 11(2):125-31. DOI: 10.1583/01-651R.1. View

Puri R, Nicholls S, Shao M, Kataoka Y, Uno K, Kapadia S . Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015; 65(13):1273-1282. DOI: 10.1016/j.jacc.2015.01.036. View

Gerassimidis T, Karkos C, Karamanos D, Kamparoudis A . Current endovascular management of the ischaemic diabetic foot. Hippokratia. 2008; 12(2):67-73. PMC: 2464305. View

Laurent S, Boutouyrie P, Cunha P, Lacolley P, Nilsson P . Concept of Extremes in Vascular Aging. Hypertension. 2019; 74(2):218-228. DOI: 10.1161/HYPERTENSIONAHA.119.12655. View

Bonaca M, Hamburg N, Creager M . Contemporary Medical Management of Peripheral Artery Disease. Circ Res. 2021; 128(12):1868-1884. DOI: 10.1161/CIRCRESAHA.121.318258. View

Konijn L, Mali W, van Overhagen H, Takx R, Veger H, de Jong P . Systemic arterial calcium burden in patients with chronic limb-threatening ischemia. J Cardiovasc Comput Tomogr. 2023; 17(3):192-200. DOI: 10.1016/j.jcct.2023.03.003. View

Criqui M, Matsushita K, Aboyans V, Hess C, Hicks C, Kwan T . Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. Circulation. 2021; 144(9):e171-e191. PMC: 9847212. DOI: 10.1161/CIR.0000000000001005. View

Brevetti G, Giugliano G, Brevetti L, Hiatt W . Inflammation in peripheral artery disease. Circulation. 2010; 122(18):1862-75. DOI: 10.1161/CIRCULATIONAHA.109.918417. View

10.

Zanoli L, Briet M, Empana J, Cunha P, Maki-Petaja K, Protogerou A . Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society. J Hypertens. 2020; 38(9):1682-1698. PMC: 7610698. DOI: 10.1097/HJH.0000000000002508. View

11.

Cooke J, Meng S . Vascular Regeneration in Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2020; 40(7):1627-1634. PMC: 7357605. DOI: 10.1161/ATVBAHA.120.312862. View

12.

Moore K, Sheedy F, Fisher E . Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013; 13(10):709-21. PMC: 4357520. DOI: 10.1038/nri3520. View

13.

Gary T, Belaj K, Hafner F, Eller P, Rief P, Hackl G . Graz Critical Limb Ischemia Score: A Risk Score for Critical Limb Ischemia in Peripheral Arterial Occlusive Disease. Medicine (Baltimore). 2015; 94(27):e1054. PMC: 4504640. DOI: 10.1097/MD.0000000000001054. View

14.

Novo S, Coppola G, Milio G . Critical limb ischemia: definition and natural history. Curr Drug Targets Cardiovasc Haematol Disord. 2004; 4(3):219-25. DOI: 10.2174/1568006043335989. View

15.

Ferreira J, Carneiro A, Vila I, Silva C, Cunha C, Longatto-Filho A . Inflammation and Loss of Skeletal Muscle Mass in Chronic Limb Threatening Ischemia. Ann Vasc Surg. 2022; 88:164-173. DOI: 10.1016/j.avsg.2022.07.009. View

16.

Signorelli S, Fiore V, Malaponte G . Inflammation and peripheral arterial disease: the value of circulating biomarkers (Review). Int J Mol Med. 2014; 33(4):777-83. DOI: 10.3892/ijmm.2014.1657. View

17.

Jalkanen J, Hautero O, Maksimow M, Jalkanen S, Hakovirta H . Correlation between increasing tissue ischemia and circulating levels of angiogenic growth factors in peripheral artery disease. Cytokine. 2018; 110:24-28. DOI: 10.1016/j.cyto.2018.04.012. View

18.

Blagov A, Markin A, Bogatyreva A, Tolstik T, Sukhorukov V, Orekhov A . The Role of Macrophages in the Pathogenesis of Atherosclerosis. Cells. 2023; 12(4). PMC: 9954519. DOI: 10.3390/cells12040522. View

19.

Kipshidze N, Chekanov V, Chawla P, Shankar L, Gosset J, Kumar K . Angiogenesis in a patient with ischemic limb induced by intramuscular injection of vascular endothelial growth factor and fibrin platform. Tex Heart Inst J. 2000; 27(2):196-200. PMC: 101055. View

20.

Hutchings G, Kruszyna L, Nawrocki M, Strauss E, Bryl R, Spaczynska J . Molecular Mechanisms Associated with ROS-Dependent Angiogenesis in Lower Extremity Artery Disease. Antioxidants (Basel). 2021; 10(5). PMC: 8148529. DOI: 10.3390/antiox10050735. View